Mesoblast's (MESO) stock has grown over 300% since we last made out an investment case in March 2019, and an IOM runthrough six months prior, based on phase 2 trial data in acute graft versus host disease (aGVHD). Presently, the United States Food and Drug Administration ((FDA)) has accepted the company’s Biologics License Application ((BLA)) for priority review of its phase 3 product candidate RYONCIL (remestemcel-L) for steroid-refractory aGVHD in children. The Prescription Drug User Fee Act (PDUFA) action date is set at 9/30/2020, and if approved, Mesoblast is geared up to make